INSP

SEC source: 0001213900-19-001091 · ownership.xml · nonDerivative · entry 6

Erony Joyce · CIK 0001459212 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,196,339

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Amzak Health Investors, LLC ("Amzak Health") on December 10, 2018.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.23 to $51.26. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8 · ownership.nature: These shares are held of record by Amzak Health. The reporting person, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. The reporting person disclaims beneficial ownership of the shares held by Amzak Health except to the extent of her proportionate pecuniary interest therein.

SEC source: 0001213900-19-001091 · ownership.xml · nonDerivative · entry 5

Erony Joyce · CIK 0001459212 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,263,771

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Amzak Health Investors, LLC ("Amzak Health") on December 10, 2018.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.455 to $51.435. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8 · ownership.nature: These shares are held of record by Amzak Health. The reporting person, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. The reporting person disclaims beneficial ownership of the shares held by Amzak Health except to the extent of her proportionate pecuniary interest therein.

SEC source: 0001104659-19-002130 · a4.xml · derivative · entry 9

Ban Randy · CIK 0001737127 · Senior VP, Sales and Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,390

Underlying: Common Stock · 5,000 shares

Expires 2022-04-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001104659-19-002130 · a4.xml · nonDerivative · entry 7

Ban Randy · CIK 0001737127 · Senior VP, Sales and Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,974

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.98 to $49.38. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-19-002130 · a4.xml · nonDerivative · entry 6

Ban Randy · CIK 0001737127 · Senior VP, Sales and Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,029

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.97 to $48.96. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-19-002130 · a4.xml · nonDerivative · entry 5

Ban Randy · CIK 0001737127 · Senior VP, Sales and Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,974

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-19-002313 · a4.xml · nonDerivative · entry 2

Herbert Timothy P. · CIK 0001737136 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Indirect · By family trust

Disclosed balance after: 244,624

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.58 to $49.38. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Shares held by the Timothy P. Herbert 2013 Family Irrevocable GST Trust U/A/D November 27, 2013.

SEC source: 0001104659-19-002313 · a4.xml · nonDerivative · entry 1

Herbert Timothy P. · CIK 0001737136 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Indirect · By family trust

Disclosed balance after: 255,824

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.58 to $48.57. The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Shares held by the Timothy P. Herbert 2013 Family Irrevocable GST Trust U/A/D November 27, 2013.

SEC source: 0001213900-19-001091 · ownership.xml · nonDerivative · entry 4

Erony Joyce · CIK 0001459212 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,294,475

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Amzak Health Investors, LLC ("Amzak Health") on December 10, 2018.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.945 to $49.50. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8 · ownership.nature: These shares are held of record by Amzak Health. The reporting person, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. The reporting person disclaims beneficial ownership of the shares held by Amzak Health except to the extent of her proportionate pecuniary interest therein.

SEC source: 0001213900-19-001091 · ownership.xml · nonDerivative · entry 3

Erony Joyce · CIK 0001459212 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,317,043

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Amzak Health Investors, LLC ("Amzak Health") on December 10, 2018.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.11 to $49.43. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8 · ownership.nature: These shares are held of record by Amzak Health. The reporting person, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. The reporting person disclaims beneficial ownership of the shares held by Amzak Health except to the extent of her proportionate pecuniary interest therein.

SEC source: 0001213900-19-001091 · ownership.xml · nonDerivative · entry 2

Erony Joyce · CIK 0001459212 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,407,043

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Amzak Health Investors, LLC ("Amzak Health") on December 10, 2018.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.11 to $48.37. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8 · ownership.nature: These shares are held of record by Amzak Health. The reporting person, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. The reporting person disclaims beneficial ownership of the shares held by Amzak Health except to the extent of her proportionate pecuniary interest therein.

SEC source: 0001104659-19-002130 · a4.xml · derivative · entry 8

Ban Randy · CIK 0001737127 · Senior VP, Sales and Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,390

Underlying: Common Stock · 5,000 shares

Expires 2022-04-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001104659-19-002130 · a4.xml · nonDerivative · entry 4

Ban Randy · CIK 0001737127 · Senior VP, Sales and Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,974

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.63 to $49.40. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-19-002130 · a4.xml · nonDerivative · entry 3

Ban Randy · CIK 0001737127 · Senior VP, Sales and Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,414

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.63 to $48.53. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-19-002130 · a4.xml · nonDerivative · entry 2

Ban Randy · CIK 0001737127 · Senior VP, Sales and Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,374

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.61 to $47.42. The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-19-002130 · a4.xml · nonDerivative · entry 1

Ban Randy · CIK 0001737127 · Senior VP, Sales and Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,974

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001213900-19-001091 · ownership.xml · nonDerivative · entry 1

Erony Joyce · CIK 0001459212 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,409,043

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Amzak Health Investors, LLC ("Amzak Health") on December 10, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.515 to $49.50. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8 · ownership.nature: These shares are held of record by Amzak Health. The reporting person, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. The reporting person disclaims beneficial ownership of the shares held by Amzak Health except to the extent of her proportionate pecuniary interest therein.

SEC source: 0001104659-19-001832 · a4.xml · nonDerivative · entry 1

Tansey Casey M · CIK 0001474322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 201,680

F1 · shares: Represents shares of vested, restricted common stock received in lieu of cash fees pursuant to the Issuer's Non-Employee Director Compensation Policy, which shares are subject to the Reporting Person's lock-up agreement entered into in connection with the Registrant's public offering of common stock consummated on December 11, 2018.

SEC source: 0001104659-19-001831 · a4.xml · nonDerivative · entry 1

NELSON MARILYN C · CIK 0001199894 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,203

F1 · shares: Represents shares of vested, restricted common stock received in lieu of cash fees pursuant to the Issuer's Non-Employee Director Compensation Policy, which shares are subject to the Reporting Person's lock-up agreement entered into in connection with the Registrant's public offering of common stock consummated on December 11, 2018.

SEC source: 0001104659-19-001830 · a4.xml · nonDerivative · entry 1

Jain Mudit K. · CIK 0001584404 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 763

F1 · shares: Represents shares of vested, restricted common stock received in lieu of cash fees pursuant to the Issuer's Non-Employee Director Compensation Policy, which shares are subject to the Reporting Person's lock-up agreement entered into in connection with the Registrant's public offering of common stock consummated on December 11, 2018.

SEC source: 0001104659-19-001829 · a4.xml · nonDerivative · entry 1

Khuong Chau Quang · CIK 0001609405 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 725

F1 · shares: Represents shares of vested, restricted common stock received in lieu of cash fees pursuant to the Issuer's Non-Employee Director Compensation Policy, which shares are subject to the Reporting Person's lock-up agreement entered into in connection with the Registrant's public offering of common stock consummated on December 11, 2018.

SEC source: 0001104659-18-073835 · a4.xml · nonDerivative · entry 3

Herbert Timothy P. · CIK 0001737136 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Indirect · By family trust

Disclosed balance after: 259,624

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.04 to $44.27. The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Shares held by the Timothy P. Herbert 2013 Family Irrevocable GST Trust U/A/D November 27, 2013.

SEC source: 0001104659-18-073835 · a4.xml · nonDerivative · entry 2

Herbert Timothy P. · CIK 0001737136 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Indirect · By family trust

Disclosed balance after: 260,524

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.81 to $43.76. The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Shares held by the Timothy P. Herbert 2013 Family Irrevocable GST Trust U/A/D November 27, 2013.

SEC source: 0001104659-18-073835 · a4.xml · nonDerivative · entry 1

Herbert Timothy P. · CIK 0001737136 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Indirect · By family trust

Disclosed balance after: 267,924

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.81 to $42.78. The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Shares held by the Timothy P. Herbert 2013 Family Irrevocable GST Trust U/A/D November 27, 2013.

SEC source: 0001104659-19-000852 · a4.xml · derivative · entry 1

Jandrich Steven · CIK 0001737203 · Chief Comp Off & VP, Human Res

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2028-12-18

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of December 18, 2018 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.

SEC source: 0001104659-19-000851 · a4.xml · derivative · entry 1

Herbert Timothy P. · CIK 0001737136 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2028-12-18

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of December 18, 2018 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.

SEC source: 0001104659-19-000849 · a4.xml · derivative · entry 1

Buchholz Richard · CIK 0001737133 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2028-12-18

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of December 18, 2018 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.

SEC source: 0001104659-19-000848 · a4.xml · derivative · entry 1

Ban Randy · CIK 0001737127 · Senior VP, Sales and Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2028-12-18

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of December 18, 2018 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.

SEC source: 0000947871-18-000971 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · Director

OrbiMed Capital GP V LLC · CIK 0001615374 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: Not disclosed

F1 · price: These shares of the Issuer's common stock were sold in a block order at a price of $37.60.

F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI V.

F3 · ownership.nature: This report on Form 4 is jointly filed by GP V and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Chau Khuong, an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.

SEC source: 0001104659-18-072861 · a4.xml · nonDerivative · entry 1

Griffin Jerry C · CIK 0001327953 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,112

SEC source: 0000947871-18-000972 · ownership.xml · nonDerivative · entry 1

Khuong Chau Quang · CIK 0001609405 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,829,449

F1 · price: These shares of the Issuer's common stock were sold in a block order at a price of $37.60.

F2 · ownership.nature: These securities are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI V. The Reporting Person is an employee of Advisors.

F3 · ownership.nature: Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001104659-18-069597 · a4.xml · nonDerivative · entry 8

Ban Randy · CIK 0001737127 · Senior VP, Sales and Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,974

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001104659-18-069597 · a4.xml · nonDerivative · entry 7

Ban Randy · CIK 0001737127 · Senior VP, Sales and Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,074

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.23 to $41.22. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-18-069597 · a4.xml · nonDerivative · entry 6

Ban Randy · CIK 0001737127 · Senior VP, Sales and Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,706

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.20 to $ 40.18. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-18-069595 · a4.xml · nonDerivative · entry 3

Herbert Timothy P. · CIK 0001737136 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Indirect · By family trust

Disclosed balance after: 274,624

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.29 to $ $41.60. The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Shares held by the Timothy P. Herbert 2013 Family Irrevocable GST Trust U/A/D November 27, 2013.

SEC source: 0001104659-18-069595 · a4.xml · nonDerivative · entry 2

Herbert Timothy P. · CIK 0001737136 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Indirect · By family trust

Disclosed balance after: 275,424

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.01 to $ $41.00. The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Shares held by the Timothy P. Herbert 2013 Family Irrevocable GST Trust U/A/D November 27, 2013.

SEC source: 0001104659-18-069595 · a4.xml · nonDerivative · entry 1

Herbert Timothy P. · CIK 0001737136 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Indirect · By family trust

Disclosed balance after: 279,489

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.01 to $ $40.00. The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Shares held by the Timothy P. Herbert 2013 Family Irrevocable GST Trust U/A/D November 27, 2013.

SEC source: 0001104659-18-069597 · a4.xml · derivative · entry 9

Ban Randy · CIK 0001737127 · Senior VP, Sales and Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,390

Underlying: Common Stock · 10,000 shares

Expires 2022-04-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001104659-18-069597 · a4.xml · nonDerivative · entry 5

Ban Randy · CIK 0001737127 · Senior VP, Sales and Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,974

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001104659-18-069597 · a4.xml · nonDerivative · entry 4

Ban Randy · CIK 0001737127 · Senior VP, Sales and Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,274

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.98 to $ $42.62. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-18-069597 · a4.xml · nonDerivative · entry 3

Ban Randy · CIK 0001737127 · Senior VP, Sales and Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,574

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.68 to $ $41.30. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-18-069597 · a4.xml · nonDerivative · entry 2

Ban Randy · CIK 0001737127 · Senior VP, Sales and Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,818

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.51 to $ $40.50. The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-18-069597 · a4.xml · nonDerivative · entry 1

Ban Randy · CIK 0001737127 · Senior VP, Sales and Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,974

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001548538-18-000007 · edgar.xml · nonDerivative · entry 9

Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner

U S Venture Partners IX L P · CIK 0001309185 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

LIDDLE DAVID E · CIK 0001212726 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

ROOT JONATHAN D · CIK 0001225480 · 10% owner

YOUNG PHILIP M · CIK 0001048637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by Philip Young

Disclosed balance after: 18,212

F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2 · ownership.direct: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

SEC source: 0001548538-18-000007 · edgar.xml · nonDerivative · entry 8

Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner

U S Venture Partners IX L P · CIK 0001309185 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

LIDDLE DAVID E · CIK 0001212726 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

ROOT JONATHAN D · CIK 0001225480 · 10% owner

YOUNG PHILIP M · CIK 0001048637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by Jonathan Root

Disclosed balance after: 18,982

F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2 · ownership.direct: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

SEC source: 0001548538-18-000007 · edgar.xml · nonDerivative · entry 7

Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner

U S Venture Partners IX L P · CIK 0001309185 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

LIDDLE DAVID E · CIK 0001212726 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

ROOT JONATHAN D · CIK 0001225480 · 10% owner

YOUNG PHILIP M · CIK 0001048637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by Paul Matteucci

Disclosed balance after: 13,356

F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2 · ownership.direct: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

SEC source: 0001548538-18-000007 · edgar.xml · nonDerivative · entry 6

Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner

U S Venture Partners IX L P · CIK 0001309185 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

LIDDLE DAVID E · CIK 0001212726 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

ROOT JONATHAN D · CIK 0001225480 · 10% owner

YOUNG PHILIP M · CIK 0001048637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by David Liddle

Disclosed balance after: 15,391

F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2 · ownership.direct: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

SEC source: 0001548538-18-000007 · edgar.xml · nonDerivative · entry 5

Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner

U S Venture Partners IX L P · CIK 0001309185 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

LIDDLE DAVID E · CIK 0001212726 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

ROOT JONATHAN D · CIK 0001225480 · 10% owner

YOUNG PHILIP M · CIK 0001048637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by Steven Krausz

Disclosed balance after: 22,573

F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2 · ownership.direct: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

SEC source: 0001548538-18-000007 · edgar.xml · nonDerivative · entry 4

Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner

U S Venture Partners IX L P · CIK 0001309185 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

LIDDLE DAVID E · CIK 0001212726 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

ROOT JONATHAN D · CIK 0001225480 · 10% owner

YOUNG PHILIP M · CIK 0001048637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Directly owned by Irwin Federman

Disclosed balance after: 18,212

F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2 · ownership.direct: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

SEC source: 0001548538-18-000007 · edgar.xml · nonDerivative · entry 3

Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner

U S Venture Partners IX L P · CIK 0001309185 · 10% owner

FEDERMAN IRWIN · CIK 0001192391 · 10% owner

KRAUSZ STEVEN M · CIK 0001190636 · 10% owner

LIDDLE DAVID E · CIK 0001212726 · 10% owner

Matteucci Paul A · CIK 0001370817 · 10% owner

ROOT JONATHAN D · CIK 0001225480 · 10% owner

YOUNG PHILIP M · CIK 0001048637 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.